{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF+cohort&page=4", "query": { "intervention": "CSF cohort", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 159, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF+cohort&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF+cohort&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T14:17:19.256Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03502330", "title": "APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Melanoma", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "APX005M", "type": "DRUG" }, { "name": "Cabiralizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2018-06-09", "completion_date": "2024-05-15", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502330" }, { "nct_id": "NCT00074750", "title": "Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "DTGM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2003-12", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074750" }, { "nct_id": "NCT00074490", "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia", "Myeloproliferative Disorders", "Multiple Myleoma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Peripheral blood stem cell (PBSC) transplantation", "type": "PROCEDURE" }, { "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells", "type": "GENETIC" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Allogeneic hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "11 Years to 90 Years" }, "enrollment_count": 442, "start_date": "2004-01-01", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074490" }, { "nct_id": "NCT00458536", "title": "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cancer" ], "interventions": [ { "name": "Dendritic Cell Tumor Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2004-10", "completion_date": "2023-07", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458536" }, { "nct_id": "NCT03920631", "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Lymphomas" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Microtransplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Ahmed Galal, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-07-10", "completion_date": "2023-05-15", "has_results": false, "last_update_posted_date": "2021-03-23", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03920631" }, { "nct_id": "NCT02769065", "title": "Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease", "Healthy Volunteers" ], "interventions": [ { "name": "TAK-071", "type": "DRUG" }, { "name": "Donepezil", "type": "DRUG" }, { "name": "TAK-071 Placebo", "type": "DRUG" }, { "name": "Donepezil Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 179, "start_date": "2016-05-05", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2019-06-10", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02769065" }, { "nct_id": "NCT01425528", "title": "Study of Kuvan Treatment in Adults With GTPCH Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "GTP Cyclohydrolase Deficiency" ], "interventions": [ { "name": "Sapropterin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2011-08", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425528" }, { "nct_id": "NCT00003597", "title": "Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant human thrombopoietin", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "1998-11", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 23, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003597" }, { "nct_id": "NCT06587828", "title": "A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autoimmune Diseases", "Ulcerative Colitis", "Multiple Sclerosis", "Scleroderma", "Ankylosing Spondylitis", "Celiac Disease", "Non-radiographic Axial Spondyloarthritis (Nr-axSpA)", "Crohn&Amp;#39;s Disease", "Birdshot Chorioretinitis" ], "interventions": [ { "name": "Companion blood samples with procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2023-01-03", "completion_date": "2026-09-10", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 11, "location_summary": "Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06587828" }, { "nct_id": "NCT06145282", "title": "Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Briquilimab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "4 Years to 100 Years" }, "enrollment_count": 6, "start_date": "2023-12-28", "completion_date": "2027-11-26", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-14T14:17:19.256Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06145282" } ] }